Significant variability in response to inhaled corticosteroids for persistent asthma.
about
Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and childrenFluticasone versus beclomethasone or budesonide for chronic asthma in adults and childrenHigh dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and childrenTBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroidsISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthmaChinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthmaChinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthmaClinical asthma phenotypes in the real world: opportunities and challengesNew combination treatments in the management of asthma: focus on fluticasone/vilanterolIdentification of innate immune response endotypes in asthma: implications for personalized medicineKey observations from the NHLBI Asthma Clinical Research NetworkGuidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendationsHLA-DQ strikes again: genome-wide association study further confirms HLA-DQ in the diagnosis of asthma among adults.Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.Asthma outcomes: exacerbationsAsthma outcomes: biomarkersPredicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines.Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide.Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.Monitoring asthma control using claims data and patient-reported outcomes measuresThe Saudi Initiative for Asthma.The role of pharmacogenomics in improving the management of asthmaAnti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma.Categorizing asthma severity: an overview of national guidelines.Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort studyOutcome of occupational asthma after removal from exposure: A follow-up study.Vitamin D levels, lung function, and steroid response in adult asthma.The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial.Lessons learned from variation in response to therapy in clinical trials.Chronic inflammation and asthma.In utero smoke exposure and impaired response to inhaled corticosteroids in children with asthma.Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patientsClassifying asthma severity and treatment determinants: national guidelines revisited.Repeatability of response to asthma medications.Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids.Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma.Pharmacogenomics of pediatric asthma.Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial.The role of inhaled and/or nasal corticosteroids on the bronchodilator responsePatterns of inhaled corticosteroid use and asthma control in the Childhood Asthma Management Program Continuation Study.
P2860
Q24243570-2F8E21FA-1E27-470C-BAED-CFB5D6EB44E9Q24246921-F1C7CFD3-E851-4CEB-80B5-C7221EA0560FQ24247765-9FED452E-5E65-472A-B7C9-E5D13CD73247Q24558608-02005024-141C-431C-89FB-6757FA780FFFQ24614404-6DE991F4-D7E5-40DC-853F-2176D5840D18Q26771615-D48982B8-9778-4C59-96A5-19E729DC3133Q26772201-E7B0C658-7821-4929-813C-1326B9BD3884Q26775236-63C1DB70-0F9A-4ACC-8BEB-B7252CEBDDDDQ26852898-B7E53726-F4DA-48BE-BCF6-392E34642742Q26860910-7B2744A9-6E27-45D6-97AC-25E13381A5CCQ27025957-B97596BD-D77E-4D42-9A10-AEC5DE55539DQ28392274-7958A9C9-5B38-4A45-86D7-6B385957EA64Q29417102-4BC5E76A-5B5C-4FA2-8F22-87FEBCF68902Q30417919-FFB4169C-F0D9-4EF4-A09A-12F4CE7EB55EQ30421935-22B2F440-F659-4CE4-8949-32E563313C70Q30425168-07513705-889F-4914-9271-8965F8325F69Q30433497-6752A10C-8FF3-4D30-B25A-6B9EE18E23B0Q30436056-4F829A36-383E-4013-9C53-6881223F4E77Q30444397-98702A58-8C7F-4BB3-BB45-E0FC9059C22AQ33502728-6BD10FF5-EC12-4B4F-A6BD-356CE3388280Q33568644-9265386B-E30B-4393-B0FF-348FEF4931A3Q33669054-E8725C61-EC60-4588-B5EF-CC83E0E25EE7Q33693320-71AFBD58-CAC7-4B73-A31B-CEDBA90214E2Q33723527-3B709001-3830-47A3-B199-0E7B0025889FQ33755127-0722259B-5D2E-4062-9E67-40606A4A7D7AQ33836175-999ABD14-69CF-40B4-A8E9-B93843676E60Q33845615-4F7C2F7E-CC33-4FE3-B128-D82DE2C7AB05Q33858088-D21EDB06-37A2-4758-8B6E-B7EBBFF9A55CQ33999050-BA30AD7F-13DC-45A9-9B95-815A8F9B1F97Q34073570-18998E29-D8BD-4210-B8BE-A03766AFFF74Q34120964-AF351FB0-6304-4700-9BCE-5D162A40DBFEQ34143925-0BE9DD10-E20A-422C-B47A-D9AC3F553C17Q34220633-A1A01214-29B4-4AC8-B392-F4A6A2456FC5Q34307611-DF81B2FA-FA45-4D68-9CEE-BDD270F7DFC8Q34318910-CC9D1C23-9A7A-4949-A1EE-39814FE9CD6CQ34388432-39119C5E-A5BF-481C-BB92-9F3153C54696Q34436523-3B7208E2-958D-4AE5-8827-C695E5CB92AFQ34443454-B89190C3-B832-445C-85F1-55D55202B5B4Q34449144-22C289FA-E331-45E7-9CCB-C4F17FDC9D91Q34582222-964B5475-3150-4173-A524-85A637FF601D
P2860
Significant variability in response to inhaled corticosteroids for persistent asthma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Significant variability in response to inhaled corticosteroids for persistent asthma.
@en
Significant variability in response to inhaled corticosteroids for persistent asthma.
@nl
type
label
Significant variability in response to inhaled corticosteroids for persistent asthma.
@en
Significant variability in response to inhaled corticosteroids for persistent asthma.
@nl
prefLabel
Significant variability in response to inhaled corticosteroids for persistent asthma.
@en
Significant variability in response to inhaled corticosteroids for persistent asthma.
@nl
P2093
P50
P356
P1476
Significant variability in response to inhaled corticosteroids for persistent asthma.
@en
P2093
Asthma Clinical Research Network of the National Heart Lung, and Blood Institute
Christine A Sorkness
Elizabeth Mauger
Elliot Israel
Homer A Boushey
James E Fish
James Kiley
Jean G Ford
Joanne K Fagan
John V Fahy
P304
P356
10.1067/MAI.2002.122635
P407
P577
2002-03-01T00:00:00Z